Effects of estrogen deprivation due to breast cancer treatment

被引:24
作者
Angelopoulos, N
Barbounis, V
Livadas, S
Kaltsas, D
Tolis, G
机构
[1] Hippokrateion Hosp Greece, Div Endocrinol & Metab, Endocrine Dept, Athens 11527, Greece
[2] St Savas Oncol Hosp, Dept Med Oncol 2, Athens 11522, Greece
关键词
D O I
10.1677/erc.1.00783
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is one of the main life-threatening diseases that a woman may have to face during her lifetime. The increasing incidence of breast neoplasia reported over the last few decades has led to widespread screening of women resulting in early diagnosis. One common but challenging question for most doctors, after the surgical excision of the lesion, is determination of the ideal adjuvant therapy for their patients for the achievement of maximum life expectancy with the best quality of life. Since the beginning of the last century, the knowledge that breast cancer arises from hormone-responsive tissues has long made use of hormone-blocking agents in the beneficial treatment of breast neoplasia. The discovery of new molecules with endocrine actions has rendered the use of adjuvant therapy in a tailor-made pattern too complicated, as these agents have a different mode of action, different adverse effects and probably different indications. The aim of the present review is to clarify these issues, analyzing the mechanism of action of available drugs and their actions on specific areas of uncertainty: cognitive function, cardiovascular system, urogenital tract, bone metabolism, weight gain, hot flushes and premature menopause. Regarding the efficacy of adjuvant therapy, there has been particular focus on the multiple hormonal-induced consequences of each regimen in order to provide the clinician with the available data for choosing the ideal therapy for the patient.
引用
收藏
页码:523 / 535
页数:13
相关论文
共 99 条
  • [1] Abe O, 1998, LANCET, V352, P930
  • [2] Influence of HRT on prognostic factors for breast cancer: a systematic review after the Women's Health Initiative trial
    Antoine, C
    Liebens, F
    Carly, B
    Pastijn, A
    Rozenberg, S
    [J]. HUMAN REPRODUCTION, 2004, 19 (03) : 741 - 756
  • [3] Armes JE, 1999, CANCER RES, V59, P2011
  • [4] Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations:: A decision analysis
    Armstrong, K
    Schwartz, JS
    Randall, T
    Rubin, SC
    Weber, B
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) : 1045 - 1054
  • [5] Baum M, 2002, LANCET, V359, P2131
  • [6] Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
    Bergman, L
    Beelen, MLR
    Gallee, MPW
    Hollema, H
    Benraadt, J
    van Leeuwen, FE
    [J]. LANCET, 2000, 356 (9233) : 881 - 887
  • [7] Menopause after breast cancer: a survey on breast cancer survivors
    Biglia, N
    Cozzarella, M
    Cacciari, F
    Ponzone, R
    Roagna, R
    Maggiorotto, F
    Sismondi, P
    [J]. MATURITAS, 2003, 45 (01) : 29 - 38
  • [8] Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/perimenopausal breast cancer patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial
    Boccardo, F
    Rubagotti, A
    Amoroso, D
    Mesiti, M
    Romeo, D
    Sismondi, P
    Giai, M
    Genta, F
    Pacini, P
    Distante, V
    Bolognesi, A
    Aldrighetii, D
    Farris, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (14) : 2718 - 2727
  • [9] Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
    Bonneterre, J
    Thürlimann, B
    Robertson, JFR
    Krzakowski, M
    Mauriac, L
    Koralewski, P
    Vergote, I
    Webster, A
    Steinberg, M
    von Euler, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) : 3748 - 3757
  • [10] Estrogen receptors α and β are differentially expressed in developing human bone
    Bord, S
    Horner, A
    Beavan, S
    Compston, E
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (05) : 2309 - 2314